evaluated potential factors associated with discordance between the self-reported and EHR-coded fracture history.Results: A total of 133 fractures from 360 women (91% white, mean[SD)] age 74.5(7.5) years, 82% had some college education) wereincluded. There were 35 fractures reported on the survey but not in theEHR and 39 fractures coded in the EHR but not in the survey. Agree-ment between self-reported and EHR fractures was k 0.48. Of the dis-cordant fractures, we were more likely to find claims for fractures inEHR referent to self-report among whites (OR=5.5, 95%CI 1.1-27.9), formajor osteoporotic fractures (OR=2.8, 95%CI 1.1-7.1), and for fragilityfractures that typically require hospitalization (vertebral, hip, femur, pelvis)(OR=3.8, 95%CI 1.3-10.7). Discordance between EHR codes and self-reported fractures did not vary by age, formal education, or healthliteracy.Conclusion: There was only modest correlation between self-reportedfracture history and EHR fracture codes. This discrepancy may haveimplications for clinical and epidemiological studies of fractures suggestingthat combining both types of data may be optimal.Disclosure of Interests:: Maria Danila Grant/research support from: Pfizer,Inc., Consultant for: Sanofi Genzyme & Regeneron, Amy Mudano: Nonedeclared, Elizabeth Rahn: None declared, Andrea LaCroix: None declared,Jeffrey Curtis: None declared, Kenneth Saag Grant/research support from:Amgen, Ironwood/AstraZeneca, Horizon, SOBI, Takeda, Consultant for:Abbvie, Amgen, Ironwood/AstraZeneca, Bayer, Gilead, Horizon, Kowa,Radius, Roche/Genentech, SOBI, Takeda, TeijinDOI: 10.1136/annrheumdis-2019-eular.4275

AB1207 ASSESSMENT OF RHEUMATIC DISEASES PATIENTSEXPERIENCE WITH THEIR HEALTHCARE USINGIEXPAC. FACTORS ASSOCIATED AND AREAS OFIMPROVEMENT:

Javier de Toro-Santos1, L María. García Vivar2, Lucía Pantoja3, CristinaLerín Lozano4, Silvia García-Díaz5, Yvonne Mestre6, Sabela Fernández6,Luis Cea-Calvo6. 1Hospital Universitario A Coruña, A Coruña, Spain; 2HospitalUniversitario de Basurto, Bilbao, Spain; 3Hospital del Bierzo, Ponferrada, Spain;4Hospital de Manacor, Manacor, Spain; 5Hospital de Sant Joan Despí MoisèsBroggi, Barcelona, Spain; 6Merck Sharp and Dohme, Madrid, Spain

Background: The experience of patients with healthcare has been associ-ated to important outcomes.Objectives: We describe the experience with healthcare of patients withrheumatic diseases from Spain self-reported through IEXPAC, a validatedquestionnaire, and the influence of demographic and health care-relatedfactors.Methods: The IEXPAC scale (“Instrument to Evaluate the EXperience ofPAtients with Chronic diseases”, http://www.iemac.es/iexpac/) was devel-oped and validated in Spain by health care professional and socialorganizations, experts in quality of healthcare and chronic patients (1). Itconsists of 12 items with Likert responses from “always” to “never” andyields an overall score from 0 (worst) to 10 (best experience). Three fac-tors with sub-scores derive from the scale: Factor 1 (productive interac-tions, average of items 1, 2, 5 and 9, on patient-health careprofessionals relationship), Factor 2 (new relational model, average ofitems 3, 7 and 11, on the use of new technologies and contact withother patients) and Factor 3 (self-management, patients’ ability to self-care, average of items 4, 6, 8 and 10). Data were obtained through ananonymous survey to patients from 25 Spanish hospitals. Bivariate com-parisons and a multivariate analysis were made to explore the associa-tion between scores and demographic and health care-relatedcharacteristics.Results: 625 patients received the survey, 359 (57.4%) returned it (meanage 55 years, 67% women). The percentage of patients who responded

“always” or “nearly always” to the different statements is displayed intable 1. Mean overall IEXPAC score was 5.5 (SD 2.0), sub-scores were:productive interactions: 7.5 (2.5); new relational model: 1.7 (2.1); self-care: 6.5 (2.5). Overall score was higher (better experience) in men (p=0.022), in those needing follow-up in a different region (p= 0.004), seenby a lower number of physicians (p= 0.025), seen by the same physicianeach time (p< 0.001), treated with lower number of medicines (p= 0.039)or with subcutaneous or intravenous (SC/IV) drugs (p= 0.083). Multiplelinear regression models (table 2) showed that being followed up by thesame physician, being seen by lower number of specialists, and beingtreated with SC/IV drugs were associated to better overall experiencescores. Associations were similar for the productive interactions and self-management factors.Conclusion: Through IEXPAC, patients with rheumatic diseases identifiedareas of improvement in healthcare, especially those related with accessto reliable information and services, interaction with other patients andcontinuity of health care after hospital discharge. Better experience wasassociated to being seen by lower number of specialists or being fol-lowed-up by the same physician each time, and also with treatment withSC/IV drugs, maybe in relation to the more personalized care thesepatients receive.

Table 1. Word-for-word IEXPAC items. Percentage of patients who responded “mostly” or“always” to each item

Scientific Abstracts 2065

on Septem

ber 4, 2021 by guest. Protected by copyright.

http://ard.bmj.com

/A

nn Rheum

Dis: first published as 10.1136/annrheum

dis-2019-eular.2759 on 27 June 2019. Dow

nloaded from

Abstract Table 2. Multivariate analysis. Variables associated to IEXPAC experience scores.Beta coeff. (SD): Beta coefficient (standard deviation). Positive coefficients indicate higherIEXPAC experience scores (better experience). SC: subcutaneous; IV: intravenous.

Acknowledgement: Funded by MSD of Spain and endorsed by 4 patients asso-ciations: ACCU, CONARTRITIS, SEISIDA, FEDE. We thank the participantpatients for providing this valuable information by completing the survey.Disclosure of Interests: Javier de Toro-Santos: None declared, María L.García Vivar: None declared, Lucía Pantoja: None declared, Cristina LerínLozano: None declared, Silvia García-Díaz: None declared, YvonneMestre Employee of: MSD, Sabela Fernández Employee of: MSD, LuisCea-Calvo Employee of: MSDDOI: 10.1136/annrheumdis-2019-eular.2759

AB1208 POINT PREVALENCE OF UVEITIS AND ARTHRITISAMONG SCHOOL CHILDREN IN A DEVELOPINGCOUNTRY

Eiman Dessouki. Faculty of medicine, Alexandria university, Alexandria, Egypt

Background: Sight-threatening uveitis associated with pediatric rheumato-logic diseases, especially juvenile idiopathi arthritis, often remains asymp-tomatic till late. On the other hand, children with indolent asymptomaticuveitis may later on develop the characteristic arthritis of juvenle idio-pathic arthritis, especially the oligoarticular rheumatoid factor negativetype. A multidiscipliary screening of children at the peak age of develop-ing these potentially handicappinng manifestations, allows active casefindng and facilitates a comprehensive ophthalmic-rheumatolgic manage-ment plan.Objectives: A point prevalence study aiming at active case finding anddescribng the prevalence of uveitis and arthritis among school childrenbetween the ages of 4 and 9 years in 10 screened schools in Egypt.Methods: All children between the ages of 4 and 9 years in 10 schoolswere screened for the clinical evidence of uveitis and/or arthritis. Thechildren discovered to be suffering from uveitis and/or arthritis, werereferred to the appropriate tertiary clinics for detailed evaluation andmanagementResults: A total of 6372 children were screened, 3418 of them werefemales (53.6%) and 2954 were males (46.4%). Thirty four children werefound to have uveitis (0.5%). Of these, 26 children were females (76.5%)and 8 children were males (23.5%). Two female children were knownuveitis patients and were on treatment. A hundred and eleven childrenhad arthralgia. Of these, 56 children had clinically evident arthritis at thetime of screening. Twenty eight children with arthritis were females (50%)and the other twenty eight children were males (50%). Three girls werepreviously known to be arthritis patients ( 2 with juvenile idiopathc arthri-tis and one with psoriasis). Sixteen children had both uveitis and arthritis.All cases detected to have uveitis, arthralgia, or arthritis, in the studywere referred to tertiary clinics for further management.Conclusion: Screening of school children for uveitis and joint manifesta-tions in developing countries with a modest socioeconomic status, is a

method of active case finding that helps an, as early as possible, imple-mentation of the proper plan of mangement.

REFERENCES[1] Kanski JJ, Shun-Shin A. Systematic uveitis syndromes in childhood; an

analysis of 340 cases. Ophthalmology 1984; 91: 1247–1252.[2] Chang JH-M, Wakefield D. Uveitis: a global perspective. Ocul Immunol

Inflamm. 2002; 10: 263–279:[3] O’Brien JM, Albert DM. Therapeutic approaches for ophthalmic problems

in juvenile arthritis. Rheumatol Dis Clin N Amer 1989; 15: 413–22.[4] Tsirouki T, Dastiridou A, Symeonidis C, et al. A focus on the epidemiology

of Uveitis. Ocul Immunol Inflamm 2016; 1–15.[5] Dollfus H. Eye involvement in children’s rheumatic diseases. Baillere’s Clin

Rheumatol 1998; 5: 197–202[6] Soylu M, Ozdemir G, Anli A. Pediatric uveitis in southern Turkey. Ocul

Immunol Inflamm 1997; 5:197–202[7] Hamade IH, Al Shamsi HN, Al Dhibi H, et al. Uveitis survey in children. Br

J Ophthalmol 2009; 93:569–572Disclosure of Interests: None declaredDOI: 10.1136/annrheumdis-2019-eular.213

AB1209 THE RHEUMA-BUS-TOUR: TWO WEEK OPEN-ACCESSSCREENING FOR EARLY RHEUMATIC DISEASES

Matthias Dreher1, Julia Sauer2, Nicolas Scharm3, Thomas Plagemann4,Gunter Assmann5, Kirsten Hoeper6, Konstantinos Triantafyllias7, ReinholdE. Schmitt8, Andreas Schwarting1,2. 1University Medical Center of the JohannesGutenberg University Mainz, Division of Rheumatology and Clinical Immunology,Mainz, Germany; 2ACURA Center of Rheumatology Rhineland-Palatinate, BadKreuznach, Germany; 3University Medical Center of the Johannes GutenbergUniversity Mainz, Clinic of Maxillofacial, Dental and Oral Diseases, Mainz,Germany; 4Leibniz University Hannover, Center for Health Economics ResearchHannover, Hannover, Germany; 5Saarland University Medical Center,Rheumatology, Homburg, Germany; 6Medical School Hannover, Center forRheumatology Lower Saxony e.V., Hannover, Germany; 7ACURA Center ofRheumatology Rhineland-Palatinate, Mainz, Germany; 8Medical School Hannover,Department of Clinical Immunology and Rheumatology, Hannover, Germany

Background: Early diagnosis is crucial for patients with rheumatic dis-eases. Studies show that early stage patients already show reducedmental and physical health [2, 3]. However, early diagnosis is oftendelayed due to the severe lack of rheumatologists in Germany.Objectives: The cross-sectional study compares data on physical andmental health of known and suspected early rheumatic patients, collectedfrom participants of the bus tour.Methods: The Rheuma-Bus-Tour is an annual, two week open-accessscreening event in three states (Rhineland-Palatine, Saarland, Lower Sax-ony) that raises awareness for rheumatic diseases and identifies peoplewith potential early cases of RA, SpA and PsA.All participants, regardless of their diagnosis status, completed a screen-ing questionnaire about early symptoms, sociodemographic as well asphysical and mental health parameters: Habitual Physical Activity Ques-tionnaire (HPA) [1], Hannover Functional Ability Questionnaire (FFbh-R),Patient Health Questionnaire (PHQ-9), Well-Being Index (WHO-5).Additionally, a CRP on-site test and a medical consultation were offered.Results: In total, 853 participants completed the questionnaire, 214 with aknown rheumatic diagnosis and 626 without one. Of 533 conducted CRPtests, 107 were positive. After the consultation, 58 patients were referredfor an immediate rheumatologist appointment through the Rheuma-VORnetwork, 16 of which were diagnosed with RA, SpA, or PsA. Tables 1and 2 present the group differences between the already diagnosed andthe not diagnosed groups, split by CRP results.

Abstract AB1209 Table 1. Basic characteristics of the participants

2066 Scientific Abstracts

on Septem

ber 4, 2021 by guest. Protected by copyright.

http://ard.bmj.com

/A

nn Rheum

Dis: first published as 10.1136/annrheum

dis-2019-eular.2759 on 27 June 2019. Dow

nloaded from